ACHV

Business Context and Reporting Period

Company: OncoGenex Pharmaceuticals, Inc. (formerly Sonus Pharmaceuticals, Inc.)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2009
Business Overview: A development-stage biopharmaceutical company focused on cancer therapies. The company completed a reverse acquisition of OncoGenex Technologies in August 2008. It has no commercial product revenue and relies on equity financing and partnerships to fund operations.

Key Financial Metrics

Note: All financial figures are in thousands of U.S. dollars unless otherwise noted.

Material Changes vs. Prior Period

• Expense Increase: Total expenses rose to $2.476 million in Q1 2009 from $1.447 million in Q1 2008.
  • R&D Expenses: Increased to $1.694 million (from $0.874 million) due to development costs for OGX-427, higher employee expenses, and facility costs from the Sonus reverse takeover. Q1 2008 included a $0.3 million tax credit offset not present in 2009.
  • G&A Expenses: Increased to $0.782 million (from $0.573 million) due to higher personnel costs and public company operating expenses.
• Investment Liquidation: Short-term investments dropped from $4.801 million at year-end 2008 to $0 at March 31, 2009, as securities were sold to fund operations. Proceeds from sales totaled $4.784 million in the quarter.
• Liability Reduction: Total liabilities decreased from $4.083 million (Dec 31, 2008) to $2.702 million (Mar 31, 2009), primarily due to the payment of manufacturing costs and amortization of restructuring liabilities.

Outlook, Risks, and Management Commentary

• Liquidity & Funding: The company has $9.393 million in cash and cash equivalents. Management believes this is sufficient to fund operations through February 2010, covering Phase 2 trials for OGX-011 and Phase 1 trials for OGX-427.
  • Capital Needs: Additional funding is required for planned Phase 3 clinical trials of OGX-011 in castrate-resistant prostate cancer (CRPC). Sources may include partnerships, licensing, or equity/debt offerings.
  • Contingency Plan: If funding is not secured in Q2 or Q3 2009, the company will reduce costs to extend operations to at least March 31, 2010.
• Restructuring: Following the August 2008 reverse takeover, the company reduced its workforce by approximately 49%. Remaining severance liabilities are estimated at $46,000. A liability of $1.403 million remains for excess facility lease obligations.
• Risk Factors:
  • Dependence on successful clinical trials and regulatory approvals.
  • Uncertainty of obtaining additional financing in a tight credit market.
  • Exposure to foreign currency fluctuations (Canadian subsidiary).
  • Commitments to pay royalties and milestone payments (up to $9.9 million to UBC/Isis and up to $14 million to Bayer) upon future product success.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $9.4 million cash balance against the timeline for Phase 3 trial initiation and the potential need for immediate capital raises.
• Lease Obligations: Confirm the status of the $1.4 million excess facility liability and the company's ability to sublet or exit the Bothell, Washington lease.
• Development Milestones: Monitor progress on OGX-011 Phase 2 trials and FDA discussions regarding Phase 3 study designs.
• Contractual Commitments: Review upcoming payment obligations to Isis Pharmaceuticals ($1.356 million for drug compound in Q2 2009) and Bayer (annual anniversary payments).
• Stock Dilution: Assess the impact of potential future equity offerings required to fund operations, given the current lack of revenue.